🇺🇸 FDA
Pipeline program

CKD-393 formulation I

A98_04BE2022P

Phase 1 small_molecule completed

Quick answer

CKD-393 formulation I for Type II Diabetes is a Phase 1 program (small_molecule) at Hong Kong Baptist University with 1 ClinicalTrials.gov record(s).

Program details

Company
Hong Kong Baptist University
Indication
Type II Diabetes
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials